Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of EDSA is 12 and suggests 220% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell